Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CLBS201 · CLBS-119, CLBS-12

Cell therapy · developed by Lisata Therapeutics

Phase 1 Most advanced trial (none active)
LSTA Developer
1 Registered trials

What is CLBS201?

CLBS201 is a cell therapy made of autologous CD34+ cells, given in a range of 1 x 10^6 to 300 x 10^6 cells. It is being studied in chronic kidney disease, including diabetic nephropathy in patients with type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CLBS-119, CLBS-12, CLBS-14
Drug type
Cell therapy
Therapy area
Endocrine, Renal & urology
Developer
Lisata Therapeutics, Inc. (LSTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
MMJ7T8VNQ7

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04990427 Phase 1 Chronic Kidney Diseases Completed LSTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney Diseases

More from Lisata Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.

Follow LSTA, the company behind CLBS201

See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LSTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.